Cited 31 times in
Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승일 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 이수현 | - |
dc.date.accessioned | 2014-12-18T09:02:36Z | - |
dc.date.available | 2014-12-18T09:02:36Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/87424 | - |
dc.description.abstract | BACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. PATIENTS AND METHODS: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-negative, stage II/III breast cancer received six cycles of 75 mg/m(2) docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). RESULTS: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. CONCLUSIONS: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | H. R. Kim | - |
dc.contributor.googleauthor | K. H. Jung | - |
dc.contributor.googleauthor | S.-A. Im | - |
dc.contributor.googleauthor | Y.-H. Im | - |
dc.contributor.googleauthor | S. Y. Kang | - |
dc.contributor.googleauthor | K. H. Park | - |
dc.contributor.googleauthor | S. Lee | - |
dc.contributor.googleauthor | S.-B. Kim | - |
dc.contributor.googleauthor | K.-H. Lee | - |
dc.contributor.googleauthor | J. S. Ahn | - |
dc.contributor.googleauthor | S. I. Kim | - |
dc.contributor.googleauthor | J. H. Sohn | - |
dc.identifier.doi | 10.1093/annonc/mds658 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A02898 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.pmid | Bevacizumab ; carboplatin ; docetaxel ; neoadjuvant chemotherapy ; pathological complete response ; triple-negative breast cancer | - |
dc.subject.keyword | Bevacizumab | - |
dc.subject.keyword | carboplatin | - |
dc.subject.keyword | docetaxel | - |
dc.subject.keyword | neoadjuvant chemotherapy | - |
dc.subject.keyword | pathological complete response | - |
dc.subject.keyword | triple-negative breast cancer | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.alternativeName | Lee, Soo Hyeon | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Lee, Soo Hyeon | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 24 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1485 | - |
dc.citation.endPage | 1490 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.24(6) : 1485-1490, 2013 | - |
dc.identifier.rimsid | 34219 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.